Toni K. Choueiri
Brigham and Women's Hospital
3 papers in the Anchorcite directory, published between 2015 and 2018, cited 16,588 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 3 papers
- Renal cell carcinoma treatment · 2 papers
- Ferroptosis and cancer prognosis · 2 papers
- Immune cells in cancer · 1 paper
- Gene expression and cancer classification · 1 paper
Frequent co-authors
- Robert John Motzer · 2 papers
- Bernard J. Escudier · 2 papers
- David F. McDermott · 2 papers
- Saby George · 2 papers
- Hans J. Hammers · 2 papers
- Elizabeth R. Plimack · 2 papers
- Daniel Castellano · 2 papers
- Howard Gurney · 2 papers
Papers
- The Immune Landscape of CancerImmunity · 2018 · 5,918 citations
We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we identified six immune subtypes-wound healing, IFN-γ dominant, inflammatory, lymphocyte depleted, immunologically quiet, and TGF-β…
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine · 2015 · 5,913 citations
BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell…
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaNew England Journal of Medicine · 2018 · 4,757 citations
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in…
Metadata from OpenAlex (CC0).